Q&A Interview With Pharmaceutical Company, BioSante Pharmaceuticals (NASDAQ: BPAX)

POINT ROBERTS, WA - November 5, 2010 (Investorideas.com newswire, www.biotechindustrystocks.com) www.investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, presents a Q&A interview with BioSante Pharmaceuticals, Inc. BPAX. Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner Mr. Stephen M. Simes, President and C.E.O. of BioSante Pharmaceuticals, discusses recent developments with its lead product in Phase III, LibiGel (testosterone gel) in addition to GVAX Pancreas Vaccine in Phase 2. Q&A Excerpt: Q: Investorideas.com Your company just recently announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events by its independent Data Monitoring Committee (DMC). Can you give investors insight into the study, the subjects and the type of data collected? A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals Yes. We currently are conducting three Phase III LibiGel clinical studies, one of which is a very important cardiovascular events and breast cancer safety study to which you refer. We now have enrolled over 2,500 women into this study and to date the safety of LibiGel looks excellent. The rate of cardiovascular events that have been reported in the study is significantly lower than was predicted for this population of women, and the rate of breast cancer reported is close to predicted. Our objective is to show the safety of LibiGel in the treatment of female sexual dysfunction for which there is no FDA approved product today. We believe we are doing that. Full interview: http://www.investorideas.com/CO/BPAX/news/11021.asp About BioSante Pharmaceuticals, Inc. BPAX Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/ Visit company website www.biosantepharma.com. Get stock alerts and news from BioSante BPAX and other stocks on Investorideas.com http://www.investorideas.com/Resources/Newsletter.asp Investorideas.com is a leading global investor and industry research resource portal specialized in sector investing. Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (three thousand per month). Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of Investor Ideas . http://www.investorideas.com/About/Disclaimer.asp Forward-Looking Statements This news release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: For info about BioSante Contact: The Trout Group LLC Tricia Swanson (646) 378-2953; tswanson@troutgroup.com Investorideas.com: 800-665-0411 cvanzant@investorideas.com More Info: Published at www.Investorideas.com - Global research by sectors If you have any questions regarding information in this press release please contact the company listed in the press release.